BCL2 and breast cancer: Its upregulation increases the sensitivity to DOX and inhibits rapidly accelerated fibrosarcoma-1 (RAF-1), which is a target gene that activates the expression of BCL-2 and P-glycoprotein (P-gp) in BC cells [74].